The field of cell gene therapy may become a gold mine for CDMO.

Wen 〡 zhikang cell gene therapy has developed into one of the most popular markets in the biopharmaceutical industry, and it is well known that in the field of cell gene therapy, production capacity is a major obstacle.
10 to 20 new cell and gene therapy candidates are likely to be approved each year by 2025, capacity expansion has become a priority for biopharmaceutical companies.
, N.J.-based CDMO, has invested $130 million in a cell gene therapy plant in Harman, Md., to expand its late-stage production capacity.
and upstream CDMO companies, including CDMO, which produces viral vectors used in gene therapy, are also making significant investments.
June, Maryland-born Emergent BioSolutions injected $75 million into its live virus vaccine plant to produce virus vectors for its growing gene therapy business.
recently, Touchlight UK hired Karen Fall, former vice president of Lonza Biopharmaceuticals, as CEO of Touchlight DNA Services, which provides contract manufacturing services for mRNA vaccines and proton DNA used in cell gene therapy.
KGaA made a similar investment in April, injecting $110m into its California virus carrier plant.
it is understood that Pfizer has adopted a "build-buy-partner" strategy to enter the gene therapy manufacturing industry and strengthen gene therapy by acquiring stakes in promising biotech companies, bringing production processes into Pfizer.
September, Pfizer teamed up with gene therapy maker Viet Therapeutics to produce a candidate for gene therapy for Wilson's disease( liver bean-like nuclear degeneration) at Pfizer's Chapel Hill plant in North Carolina.
Over the past few years, Pfizer has invested about $800 million to expand three plants in North Carolina, including the Chapel Hill plant, which means it can produce multiple gene therapy candidates in parallel and open the door to bringing in other partners.
as early as May 2019, Pfizer acquired a 15% stake in Vivat and had the exclusive option to acquire the company entirely.
Pfizer and BioNTech have also reached an agreement with German contract manufacturer Reentschler Biopharma, which is responsible for the downstream purification of the mRNA vaccine for both companies.
BioNTech last month acquired Novartis Pharmaceuticals' German biopharmaceutical plant and is expected to be fully operational in the first half of 2021, with plans to produce 750 million doses of vaccine per year.
.